throbber
FDA Approves First-Of-Its-Kind Breast Cancer Drug
`
`iOS app Android app More
`
`Log in
`
`Create Account
`
`December 5, 2014
`
`Edition: U.S.
`
`Like
`
`187k
`
`
`
`Follow
`
`
`
`Newsletters
`
`
`
`Huffington Post Search
`
`FRONT PAGE
`WOMEN
`TASTE
`GOOD NEWS
`PARENTS
`STYLE
`POST50
`RELIGION
`WEDDINGS
`HUFFPOST LIVE
`ALL SECTIONS
`Healthy Living • Health And Fitness • GPS for the Soul • Health News • Sleep • Healthy Living Videos • Moments Not Milestones • Lifestyle • Third Metric • Thrive
`
`7 Of The Best Ab Exercises You're
`Probably Not Doing
`
`Could Depression Be Caused By A
`Virus?
`
`Immediately Responding To Work
`Email Is Actually Making You Worse
`At Your Job
`
`
`
`Tur
`Pro
`
`
`
`
`
`
`
`FDA Approves First-Of-Its-Kind
`Breast Cancer Drug
`
` | By MATTHEW PERRONE
`
`Posted: 02/22/2013 12:30 pm EST
`
`Updated: 02/18/2014 8:59 am EST
`
`ADVERTISEMENT
`
`228
`
`Like
`
`69
`
`0
`
`0
`
`38
`
`25
`
`Share
`
`Tweet
`
`Email
`
`Comment
`
`The Food and Drug Administration has approved a first-of-a-kind breast cancer
`medication that targets tumor cells while sparing healthy ones.
`
`The drug Kadcyla from Roche combines the established drug Herceptin with a
`powerful chemotherapy drug and a third chemical linking the medicines together.
`The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a
`potent dose of anti-tumor poison.
`
`Cancer researchers say the drug is an important step forward because it delivers
`more medication while reducing the unpleasant side effects of chemotherapy.
`
`Sponsored Links
`LifeLock.com
`LifeLock® Data Breach Notifications Help
`Protect Your Identity.
`LifeLock.com
`Stop Suffering From Nerve Pain
`Clinical studies find natural formula to be
`highly effective. Try it FREE*
`www.NeuropathyTreatmentGroup.com
`Odd Trick Fights Diabetes
`"Unique" Proven Method To Control Blood
`Sugar In 3 Weeks. Watch Video
`Smart-Consumer-Lifestyles.com
`
` Buy a link here
`
`"This antibody goes seeking out the
`tumor cells, gets internalized and then
`explodes them from within. So it's
`very kind and gentle on the patients –
`there's no hair loss, no nausea, no
`vomiting," said Dr. Melody Cobleigh
`of Rush University Medical Center.
`"It's a revolutionary way of treating
`cancer."
`
`Cobleigh helped conduct the key
`studies of the drug at the Chicago
`facility.
`
`The FDA approved the new treatment for about 20 percent of breast cancer patients
`with a form of the disease that is typically more aggressive and less responsive to
`hormone therapy. These patients have tumors that overproduce a protein known as
`HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and
`is expected to kill more than 39,000 Americans this year, according to the National
`Cancer Institute.
`
`The approval will help Roche's Genentech unit build on the blockbuster success of
`Herceptin, which has long dominated the breast cancer marketplace. The drug had
`sales of roughly $6 billion last year.
`
`FROM OUR PARTNERS
`
`9 Surprising Signs of
`Depression
`
`10 Foods Guaranteed
`To Help You Sleep
`Better
`
`The Weird Sign You
`May Have Skin Cancer
`
`The Simple Thing You
`Can Do In The Morning
`To Lose Weight
`
`SUGGESTED FOR YOU
`Why Burt Reynolds' Ex-Wife Is Getting
`Rid Of Everything He Gave Her
`
`http://www.huffingtonpost.com/2013/02/22/fda-approves-new-breast-cancer-drug-kadcyla_n_2742241.html[12/5/2014 10:43:15 AM]
`
`IMMUNOGEN 2133, pg. 1
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`
`FDA Approves First-Of-Its-Kind Breast Cancer Drug
`
`Genentech said Friday that Kadcyla will cost $9,800 per month, compared to
`$4,500 per month for regular Herceptin. The company estimates a full course of
`Kadcyla, about nine months of medicine, will cost $94,000.
`
`FDA scientists said they approved the drug based on company studies showing
`Kadcyla delayed the progression of breast cancer by several months. Researchers
`reported last year that patients treated with the drug lived 9.6 months before death
`or the spread of their disease, compared with a little more than six months for
`patients treated with two other standard drugs, Tykerb and Xeloda.
`
`Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for
`patients taking the other drugs.
`
`FDA specifically approved the drug for patients with advanced breast cancer who
`have already been treated with Herceptin and taxane, a widely used chemotherapy
`drug. Doctors are not required to follow FDA prescribing guidelines, and cancer
`researchers say the drug could have great potential in patients with earlier forms of
`breast cancer
`
`Kadcyla will carry a boxed warning, the most severe type, alerting doctors and
`patients that the drug can cause liver toxicity, heart problems and potentially death.
`The drug can also cause severe birth defects and should not be used by pregnant
`women.
`
`Kadcyla was developed by South San Francisco-based Genentech using drug-
`binding technology licensed from Waltham, Mass.-based ImmunoGen. The company
`developed the chemical that keeps the drug cocktail together and is scheduled to
`receive a $10.5 million payment from Genentech on the FDA decision. The company
`will also receive additional royalties on the drug's sales.
`
`Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock
`has ttraded in a 52-wek range of $10.85 to $18.10.
`
`RELATED ON HUFFPOST:
`
`Celebrities Who Have Faced Breast Cancer
`
`1 of 16
`
`Close
`
`
`AP
`
`
`
`Kadcyla Breast Cancer Drug, Kadcyla, Breast Cancer, New Breast Cancer Drug Approved, Breast
`MORE:
`Cancer Drug Approved, Breast Cancer Drug, Kadcyla Approved,
`
`Suggest a
`correction
`
`http://www.huffingtonpost.com/2013/02/22/fda-approves-new-breast-cancer-drug-kadcyla_n_2742241.html[12/5/2014 10:43:15 AM]
`
`Jenna Bush Hager: 'I'm Fiercely
`Protective' Of Sasha And Malia Obama
`
`'30 Rock' May Have Called Out Bill
`Cosby For Sexual Assault Back In 2009
`
`These Striking Wedding Photos From
`Kenya Will Take Your Breath Away
`
`Prince Harry Reveals Secret On World
`AIDS Day, Helps Fight Stigma
`
`Reality Star Kristin Cavallari 'Felt Very,
`Very Used And Manipulated' By MTV
`
`A Surprising Treatment For Depression
`That May Be Just As Effective As
`Talking To A Therapist
`
`7 Brothers Give Bride The Wedding Gift
`To End All Wedding Gifts
`
`IMMUNOGEN 2133, pg. 2
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`
`FDA Approves First-Of-Its-Kind Breast Cancer Drug
`
`Promoted Links by Taboola
`
`WTF Is Jaggery, Anyway?
`
`10 Secrets That Will
`Whiten Teeth
`WedMD
`
`87 Yr Old Trainer
`Shares Secret To
`Losing Weight
`Athletic Greens
`
`8 Signs to Call It Quits
`on a Relationship
`The Daily 8
`
`This Edible Holiday Gift Will Have
`Everyone Raving
`
`28 Celebs Who Have
`Severe Illnesses
`PressroomVIP
`
`ADHD Affects Adults: 5
`Signs
`WebMD
`
`'The Bachelorette' Star
`Josh Murray Is More
`Than 'Former Pro Bas…
`ThePostGame
`
`FOLLOW HUFFPOST
`
`Around the Web
`
` Breast cancer: Treatments and drugs - MayoClinic.com
` Drugs Approved for Breast Cancer - National Cancer Institute
` F.D.A. Revokes Approval of Avastin for Use as Breast Cancer Drug ...
` Drug Approved for Breast Cancer - WSJ.com
` What's new in breast cancer research and treatment?
` Breast Cancer Drug Approved - CBS News Video
` FDA Gives Nod to New Breast Cancer Drug - US News and World ...
`
` The Morning Email
`
`
`
` Healthy Living
`
`Get top stories and blog posts emailed to me each day..
`
`Advertise
`
`Log In
`
`Make HuffPost Your Home Page
`
`RSS
`
`Careers
`
`FAQ
`
`User Agreement
`
`Privacy
`
`Comment Policy
`
`About Us
`
`About Our Ads
`
`Contact Us
`
`Copyright ©2014 TheHuffingtonPost.com, Inc.
`
` "The Huffington Post" is a registered trademark of TheHuffingtonPost.com, Inc. All rights reserved.
`
`Part of AOL Lifestyle
`
`http://www.huffingtonpost.com/2013/02/22/fda-approves-new-breast-cancer-drug-kadcyla_n_2742241.html[12/5/2014 10:43:15 AM]
`
`IMMUNOGEN 2133, pg. 3
`Phigenix v. Immunogen
`IPR2014-00676

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket